OliX Pharmaceuticals Expands Ocular Disease Pipeline; Adds OLX304A for the Treatment of Retinitis Pigmentosa
SUWON, South Korea, May 10, 2019 /PRNewswire/ — OliX Pharmaceuticals, Inc. (KOSDAQ: 226950), a leading developer of RNAi therapeutics, announced today an expansion of its ocular disease pipeline. Specifically, the…